Transformation of bioactive compounds by Fusarium sacchari fungus isolated from the soil-cultivated ginseng

Journal of Agricultural and Food Chemistry

Volumn 55, Issue 23, 2007, Pages 9373-9379

  Han, Ying ^a   Sun, Baoshan ^b   Hu, Xiaomin ^a   Zhang, Hong ^c   Jiang, Binhui ^a   Spranger, Maria Isabel ^b   Zhao, Yuqing ^c  

^a NORTHEASTERN UNIVERSITY   (China)

^b Estacao Vitivinicola Nacional   (Portugal)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antitumor activity; Bioactive compound; Compound K; Compound Mx; Fusarium sacchari; Ginsenoside Mc; Transformation

Indexed keywords

ANTINEOPLASTIC AGENT; GINSENOSIDE; GINSENOSIDE M1; GINSENOSIDE MC; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL LINE; FUSARIUM; GINSENG; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; FUSARIUM; GINSENOSIDES; MICE; NEOPLASM TRANSPLANTATION; PANAX;

FUNGI; FUSARIUM; FUSARIUM SACCHARI; PANAX GINSENG; RATTUS;

EID: 36749053972     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf070354a     Document Type: Article

References (45)

1. Kwan, C. Y.; Kwan, T. K. Effects of Panax notoginseng saponins on vascular endothelial cells in vitro. Acta Pharmacol. Sin. 2000, 21, 1101-1105.
2. Li, S. H.; Chu, Y. Anti-inflammation effects of total saponins of Panax notoginseng. Acta Pharmacol. Sin. 1999, 6, 551-555.
3. Yoshikawa, M.; Murakami, T.; Ueno, T. Bioactive saponins and glycosides. VIII. Notoginseng (1): new dammarane-type triterpene oligoglycosides, notoginsenosides-A, -B, -C, and -D, from the dried root of Panax notoginseng (Burk.) F.H. Chen. Chem. Pharm. Bull. (Tokyo) 1997, 45, 1039-1045.
4. Yoshikawa, M.; Morikawa, T.; Yashiro, K.; Murakami, T.; Matsuda, H. Bioactive saponins and glycosides. XIX. Notoginseng (3): immunological adjuvant activity of notoginsenosides and related saponins: structures of notoginsenosides-L, -M, and -N from the roots of Panax notoginseng (Burk.) F.H. Chen. Chem. Pharm. Bull. (Tokyo) 2001, 49, 1452-1456.
5. Yoshikawa, M.; Morikawa, T.; Kashima, Y.; Ninomiya, K.; Matsuda, H. Structures of new dammarane-type triterpene saponins from the flower buds of Panax notoginseng and hepatoprotective effects of principal ginseng saponins. J. Nat. Prod. 2003, 66, 922-927.
6. Du, Q.; Jerz, G.; Waibel, R.; Winterhalter, P. Isolation of dammarane saponins from Panax notoginseng by high-speed counter-current chromatography. J. Chromatogr. 2003, 1008, 173-180.
7. 3. Chem. Pharm. Bull. (Tokyo) 2005, 53, 177-179.
8. Gillis, C. N. Panax ginseng pharmacology: a nitric oxide link. Biochem. Pharmacol. 1997, 54, 1-8.
9. Attele, A. S.; Wu, J. A.; Yuan, C. S. Ginseng pharmacology. Biochem. Pharmacol. 1999, 58, 1685-1693.
10. Shibata, S. Chemistry and cancer preventing activities of Ginseng saponins and some related triterpenoid compounds. J. Korean Med. Sci. 2001, 16, S28-S37.
11. 2 in the digestive tract of rats. Chem. Pharm. Bull. 1991, 39, 2357-2361.
12. Hasegawa, H.; Sung, J. H.; Matsumiya, S. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med. 1996, 62, 453-457.
13. Hasegawa, H.; Sung, J. H.; Benno, Y. Role of human intestinal Prevotella oris in hydrolyzing Ginseng saponins. Planta Med. 1997, 63, 436-440.
14. Hasegawa, H.; Lee, K. S.; Nagaoka, T. Pharmacokinetics of ginsenoside deglycosylated by intestinal bacteria and its transformation to biologically active fatty acid esters. Biol. Pharm. Bull. 2000, 23, 298-304.
15. 1 from Panax ginseng. J. Pharm. Pharmacol. 1998, 50, 1155-1160.
16. 1 by intestinal bacteria, in rat plasma after oral administration: measurement of compound K by enzyme immunoassay. Biol. Pharm. Bull. 1998, 21, 245-249.
17. Wakabayashi, C.; Murakami, K.; Hasegawa, H. An intestinal bacterial metabolite of ginseng protopanaxadiol saponins has the ability to induce apoptosis in tumor cells. Biochem. Biophys. Res. Commun. 1998, 246, 725-730.
18. 2 from human intestinal bacteria. Biol. Pharm. Bull. 2000, 23, 1481-1485.
19. 1 by human intestinal bacteria and its related antiallergic activity. Biol. Pharm. Bull. 2002, 25, 743-747.
20. Tawab, M. A.; Bahr, U.; Karas, M. Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos. 2003, 31, 1065-1071.
21. 1 and Re from Panax ginseng by food microorganisms. Biotechnol. Lett. 2005, 27, 765-771.
22. 2 and Rc from Panax ginseng by food microorganisms. Biol. Pharm. Bull. 2005, 28, 2102-2105.
23. Kang, K. A.; Kim, Y. W.; Kim, S. U.; Chae, S.; Koh, Y. S.; Kim, H. S.; Choo, M. K.; Kim, D. H.; Hyun, J. W. G1 phase arrest of the cell cycle by a ginseng metabolite, compound K, in U937 human monocytic leukamia cells. Arch. Pharmacal Res. 2005, 28, 685-690.
24. Hasegawa, H.; Sung, J. H.; Matsumiya, S. Reversal of daunomycin and vinblastine resistance in multidrugresistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Planta Med. 1995, 61, 409-413.
25. 1 in dependence on intestinal bacterial hydrolyzing potential and significance of treatment with an active bacterial metabolite. Planta Med. 1998, 64, 696-700.
26. Lee, S. J.; Sung, J. H.; Lee, S. J. Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin. Cancer Lett. 1999, 144, 39-43.
27. Lee, S. J.; Go, W. G.; Kim, J. H. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem. Pharmacol. 2000, 60, 677-685.
28. Kang, J. K.; Lee, Y. J.; No, K. O. Ginseng intestinal metabolite-I (GIM-I) reduces doxorubicin toxicity in the mouse testis. Reprod. Toxicol. 2002, 16, 291-298.
29. Choo, M. K.; Park, E. K.; Han, M. J. Antiallergic activity of ginseng and its ginsenosides. Planta Med. 2003, 69, 518-522.
30. Kim, D. H.; Jung, J. S.; Moon, Y. S. Inhibition of intracerebroventricular injection stress-induced plasma corticosterone levels by intracerebroventricularly administered compound K, a ginseng saponin metabolite, in mice. Biol. Pharm. Bull. 2003, 26, 1035-1038.
31. Binghui, J.; Yuqing, Z.; Chengzhi, W. Isolation and Identification of minor Bioactive Saponins from the Leaves of Panax notoginseng (Burk.) F.H. Chen. Chin. Med. Mat. 2004, 27, 489-491.
32. Binghui, J.; Yuqing, Z.; Ying, H.; Xiaomin, H.; Longxi, Z. Isolation and Structural Determination of Enzymatic Hydrolysates of the Leaves Saponins of Panax notoginseng. Chin. J. Nat. Med. 2004, 4202-204.
33. Binghui, J.; Yuqing, Z. Study on optimization of enzymatic translation for preparation ginsenoside C-K in the Leaves Saponins of Panax Notoginseng. Chin. Tradit. Herb. Drugs 2003, 34, 516-518.
34. Binghui, J.; Yuqing, Z.; Ying, H.; Yu, C.; Xiaomin, H. Enzymatic Transformation of Notoginsenoside Fe by β-Glucanase. J. Chin. Pharm. Sci. 2006, 15, 6-9.
35. Ming, Y.; Yuqing, Z. Studies on Triterpenes from the Fruit of Panax Gingeng. Chin. Tradit. Herb. Drugs 2004, 35, 869-870.
36. Chen, Y.; Zhan, E.; Chen, H. Saponins with low sugar chain from the leaves of Panax notogiseng (Burk.) F.H. Chen. Chin. Tradit. Herb. Drugs 2002, 25, 176-178.
37. 3. Chem. Pharm. Bull. 2005, 53, 177-179.
38. 3 by human intestinal bacteria and its relation to in vitro biological activities. Biol. Pharm. Bull. 2002, 25, 58-63.
39. 1, and F1 from protopanaxatriol-type ginseng saponin mixture. Planta Med. 2003, 69, 285-286.
40. 1, and crude Sanchi saponins by human intestinal microflora. J. Chin. Chem. Soc. 2001, 48, 113-120.
41. 1 by Rhizopus stolonifer and Curvularia lunata. Biotechnol. Lett. 2003, 25, 339-344.
42. Lee, J. Y.; Shin, J. W.; Chun, K. C. Antitumor promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin. Carcinogenesis 2005, 26, 359-367.
43. Atopkina, L. N.; Malinovskaya, G. V.; Elyakov, G. B.; Uvarova, N. I.; Woerdenbag, H. J.; Koulman, A.; Ras, N.; Potier, P. Cytotoxicity of natural ginseng glycosides and semisynthetic analogues. Planta Med. 1999, 65, 30-34.
44. Popovich, D. G.; Kitts, D. D. Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch. Biochem. Biophys. 2002, 406, 1-8.
45. 3. Chin. J. Cancer Prev. Treat. 2004, 11, 957-958.